Axsome Therapeutics (AXSM) insider plans Rule 144 sale of 12,000 shares

Rhea-AI Filing Summary

Axsome Therapeutics, Inc. filed a notice of proposed insider sale of 12,000 common shares under Rule 144. The shares are to be sold through Charles Schwab & Co., Inc. on NASDAQ, with an aggregate market value of 2,254,989.00. The filing notes that there were 50,412,640 common shares outstanding at the time of the notice.

The 12,000 shares were acquired on 01/22/2026 through an employee stock option exercise from Axsome Therapeutics, Inc. The exercise was structured as a broker-facilitated cashless exercise, meaning the broker handled payment in connection with the transaction. The person on whose behalf the sale is planned represents that they are not aware of any material adverse, nonpublic information about the company’s operations.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	12000	2254989.00	50412640	01/22/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/22/2026	Employee Stock Option Exercise	Axsome Therapeutics, Inc.			12000	01/22/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Rule 144 filing for AXSM disclose?

The filing discloses a planned sale of 12,000 shares of Axsome Therapeutics, Inc. common stock under Rule 144, to be executed through Charles Schwab & Co., Inc. on NASDAQ.

How many Axsome Therapeutics (AXSM) shares are proposed to be sold?

The notice covers a proposed sale of 12,000 common shares of Axsome Therapeutics, Inc., with an aggregate market value of 2,254,989.00 as stated in the filing.

How were the AXSM shares in this Rule 144 filing acquired?

The 12,000 common shares were acquired on 01/22/2026 via an employee stock option exercise from Axsome Therapeutics, Inc.

What payment method was used for the AXSM option exercise?

The filing states the exercise was completed through a broker payment for cashless exercise, meaning the broker arranged payment in connection with the transaction.

How many Axsome Therapeutics (AXSM) shares were outstanding at the time of the notice?

The filing reports that 50,412,640 common shares of Axsome Therapeutics, Inc. were outstanding when the notice was prepared; this is a baseline share count.

Does the AXSM Rule 144 seller make any representation about nonpublic information?

Yes. By signing the notice, the seller represents that they do not know any material adverse information about Axsome Therapeutics, Inc. that has not been publicly disclosed.